David R Brown

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2765732/publications.pdf

Version: 2024-02-01

162 papers	11,881 citations	26610 56 h-index	30058 103 g-index
165 all docs	165 docs citations	165 times ranked	7052 citing authors

#	Article	IF	Citations
1	The cellular prion protein binds copper in vivo. Nature, 1997, 390, 684-687.	13.7	1,170
2	Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature, 1996, 380, 345-347.	13.7	506
3	Normal prion protein has an activity like that of superoxide dismutase. Biochemical Journal, 1999, 344, 1-5.	1.7	461
4	Prion Protein-Deficient Cells Show Altered Response to Oxidative Stress Due to Decreased SOD-1 Activity. Experimental Neurology, 1997, 146, 104-112.	2.0	398
5	Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases. Dalton Transactions, 2004, , 1907.	1.6	326
6	Prion protein expression and superoxide dismutase activity. Biochemical Journal, 1998, 334, 423-429.	1.7	245
7	Preferential Cu2+ Coordination by His96 and His111 Induces Î²-Sheet Formation in the Unstructured Amyloidogenic Region of the Prion Protein. Journal of Biological Chemistry, 2004, 279, 32018-32027.	1.6	218
8	Role of Microglia in Neuronal Cell Death in Prion Disease. Brain Pathology, 1998, 8, 449-457.	2.1	209
9	Normal prion protein has an activity like that of superoxide dismutase. Biochemical Journal, 1999, 344, 1.	1.7	205
10	Lack of prion protein expression results in a neuronal phenotype sensitive to stress. Journal of Neuroscience Research, 2002, 67, 211-224.	1.3	204
11	Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment. NeuroReport, 1994, 5, 2057-2060.	0.6	199
12	Antioxidant activity related to copper binding of native prion protein. Journal of Neurochemistry, 2008, 76, 69-76.	2.1	197
13	Immunization Delays the Onset of Prion Disease in Mice. American Journal of Pathology, 2002, 161, 13-17.	1.9	182
14	Aberrant metal binding by prion protein in human prion disease. Journal of Neurochemistry, 2001, 78, 1400-1408.	2.1	178
15	Prion and prejudice: normal protein and the synapse. Trends in Neurosciences, 2001, 24, 85-90.	4.2	177
16	Copper Chelation Delays the Onset of Prion Disease. Journal of Biological Chemistry, 2003, 278, 46199-46202.	1.6	170
17	Seeking a Mechanism for the Toxicity of Oligomeric Î±-Synuclein. Biomolecules, 2015, 5, 282-305.	1.8	168
18	Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. Journal of Neurochemistry, 2001, 76, 565-572.	2.1	163

#	Article	IF	Citations
19	Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochemical Journal, 2002, 362, 253-258.	1.7	156
20	Microglia and the aging brain: are senescent microglia the key to neurodegeneration?. Journal of Neurochemistry, 2019, 151, 676-688.	2.1	150
21	Probing Copper2+ Binding to the Prion Protein Using Diamagnetic Nickel2+ and 1H NMR: The Unstructured N terminus Facilitates the Coordination of Six Copper2+ Ions at Physiological Concentrations. Journal of Molecular Biology, 2005, 346, 1393-1407.	2.0	148
22	Alpha-Synuclein Is a Cellular Ferrireductase. PLoS ONE, 2011, 6, e15814.	1.1	144
23	Effects of Copper on Survival of Prion Protein Knockout Neurons and Glia. Journal of Neurochemistry, 1998, 70, 1686-1693.	2.1	143
24	Emergent Synchronous Bursting of Oxytocin Neuronal Network. PLoS Computational Biology, 2008, 4, e1000123.	1.5	131
25	Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. Journal of Neurochemistry, 2008, 79, 689-698.	2.1	130
26	Unique copperâ€induced oligomers mediate alphaâ€synuclein toxicity. FASEB Journal, 2009, 23, 2384-2393.	0.2	129
27	Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochemical Journal, 2002, 362, 253.	1.7	119
28	High Affinity Binding between Copper and Full-length Prion Protein Identified by Two Different Techniques. Journal of Biological Chemistry, 2005, 280, 42750-42758.	1.6	109
29	Copper binding regulates intracellular alphaâ€synuclein localisation, aggregation and toxicity. Journal of Neurochemistry, 2010, 113, 704-714.	2.1	104
30	Effects of oxidative stress on prion protein expression in pc12 cells. International Journal of Developmental Neuroscience, 1997, 15, 961-972.	0.7	103
31	Prion protein fate governed by metal binding. Biochemical and Biophysical Research Communications, 2004, 325, 1005-1012.	1.0	100
32	Deconvoluting the Cu2+ Binding Modes of Full-length Prion Protein*. Journal of Biological Chemistry, 2008, 283, 1870-1881.	1.6	97
33	Prion protein expression aids cellular uptake and veratridine-induced release of copper. , 1999, 58, 717-725.		95
34	Prion Protein Peptide Neurotoxicity Can Be Mediated by Astrocytes. Journal of Neurochemistry, 2001, 73, 1105-1113.	2.1	94
35	Manganese Binding to the Prion Protein. Journal of Biological Chemistry, 2008, 283, 12831-12839.	1.6	90
36	Microglia and prion disease. Microscopy Research and Technique, 2001, 54, 71-80.	1.2	89

#	Article	IF	Citations
37	The cellular prion protein traps Alzheimer's AÎ² in an oligomeric form and disassembles amyloid fibers. FASEB Journal, 2013, 27, 1847-1858.	0.2	89
38	Prion Protein Peptides: Optimal Toxicity and Peptide Blockade of Toxicity. Molecular and Cellular Neurosciences, 2000, 15, 66-78.	1.0	85
39	A neurotoxic prion protein fragment enhances proliferation of microglia but not astrocytes in culture. , 1996, 18, 59-67.		82
40	Selective Oxidation of Methionine Residues in Prion Proteins. Biochemical and Biophysical Research Communications, 1999, 259, 352-355.	1.0	81
41	Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathologica, 2005, 43, 229-43.	0.5	80
42	Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma. Molecular and Cellular Proteomics, 2009, 8, 1501-1515.	2.5	78
43	Microglial expression of the prion protein. NeuroReport, 1998, 9, 1425-1429.	0.6	75
44	Prion protein does not redox-silence Cu2+, but is a sacrificial quencher of hydroxyl radicals. Free Radical Biology and Medicine, 2007, 42, 79-89.	1.3	74
45	Role of the prion protein in copper turnover in astrocytes. Neurobiology of Disease, 2004, 15, 534-543.	2.1	73
46	Brain proteins that mind metals: a neurodegenerative perspective. Dalton Transactions, 2009, , 4069.	1.6	72
47	Copper(II) complexes of peptide fragments of the prion protein. Conformation changes induced by copper(II) and the binding motif in C-terminal protein region. Journal of Inorganic Biochemistry, 2004, 98, 133-143.	1.5	71
48	Astrocytic glutamate uptake and prion protein expression. , 1999, 25, 282-292.		70
49	Early Onset Prion Disease from Octarepeat Expansion Correlates with Copper Binding Properties. PLoS Pathogens, 2009, 5, e1000390.	2.1	70
50	The Synucleins Are a Family of Redox-Active Copper Binding Proteins. Biochemistry, 2011, 50, 37-47.	1.2	66
51	Elevated manganese levels in blood and CNS in human prion disease. Molecular and Cellular Neurosciences, 2008, 37, 590-598.	1.0	65
52	Neurons Depend on Astrocytes in a Coculture System for Protection from Glutamate Toxicity. Molecular and Cellular Neurosciences, 1999, 13, 379-389.	1.0	64
53	Induction of HO-1 and NOS in Doppel-Expressing Mice Devoid of PrP: Implications for Doppel Function. Molecular and Cellular Neurosciences, 2001, 17, 768-775.	1.0	62
54	Prion protein expression in muscle cells and toxicity of a prion protein fragment. European Journal of Cell Biology, 1998, 75, 29-37.	1.6	61

#	Article	IF	Citations
55	PrP and Î²-Amyloid Fragments Activate Different Neurotoxic Mechanisms in Cultured Mouse Cells. European Journal of Neuroscience, 1997, 9, 1162-1169.	1.2	60
56	The chemistry of copper binding to PrP: is there sufficient evidence to elucidate a role for copper in protein function?. Biochemical Journal, 2008, 410, 237-244.	1.7	60
57	Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease. Vaccine, 2015, 33, 726-733.	1.7	60
58	Amyloid-Î² and Proinflammatory Cytokines Utilize a Prion Protein-Dependent Pathway to Activate NADPH Oxidase and Induce Cofilin-Actin Rods in Hippocampal Neurons. PLoS ONE, 2014, 9, e95995.	1.1	58
59	Synthesis of Analogues of Congo Red and Evaluation of Their Anti-Prion Activity. Journal of Medicinal Chemistry, 2004, 47, 5515-5534.	2.9	57
60	Removal of glucuronic acid from xylan is a strategy to improve the conversion of plant biomass to sugars for bioenergy. Biotechnology for Biofuels, 2017, 10, 224.	6.2	57
61	PrPSc-like prion protein peptide inhibits the function of cellular prion protein. Biochemical Journal, 2000, 352, 511-518.	1.7	57
62	Copper Refolding of Prion Protein. Biochemical and Biophysical Research Communications, 2000, 276, 1217-1224.	1.0	56
63	Thermodynamic and Voltammetric Characterization of the Metal Binding to the Prion Protein: Insights into pH Dependence and Redox Chemistry. Biochemistry, 2009, 48, 2610-2619.	1.2	53
64	Metal binding to alpha-synuclein peptides and its contribution to toxicity. Biochemical and Biophysical Research Communications, 2009, 380, 377-381.	1.0	53
65	Copper(II)-Induced Secondary Structure Changes and Reduced Folding Stability of the Prion Protein. Journal of Molecular Biology, 2011, 410, 369-382.	2.0	52
66	Copper binding is the governing determinant of prion protein turnover. Molecular and Cellular Neurosciences, 2005, 30, 186-196.	1.0	50
67	Î±-Synuclein as a ferrireductase. Biochemical Society Transactions, 2013, 41, 1513-1517.	1.6	50
68	Manganese Enhances Prion Protein Survival in Model Soils and Increases Prion Infectivity to Cells. PLoS ONE, 2009, 4, e7518.	1.1	50
69	Elevated manganese levels in blood and central nervous system occur before onset of clinical signs in scrapie and bovine spongiform encephalopathy. Journal of Animal Science, 2007, 85, 1596-1609.	0.2	49
70	Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. Journal of Pathology, 2004, 203, 603-608.	2.1	48
71	Methionine Oxidation Perturbs the Structural Core of the Prion Protein and Suggests a Generic Misfolding Pathway. Journal of Biological Chemistry, 2012, 287, 28263-28275.	1.6	48
72	Copper-Dependent Functions for the Prion Protein. Molecular Biotechnology, 2002, 22, 165-178.	1.3	47

#	Article	IF	Citations
73	Interactions between metals and Î±â€synucleinâ€ƒâ^'â€ƒfunction or artefact?. FEBS Journal, 2007, 274, 3766-3774.	2.2	47
74	Generation of Hydrogen Peroxide from Mutant Forms of the Prion Protein Fragment PrP121â^'231â€. Biochemistry, 2003, 42, 7675-7681.	1.2	45
75	The effects of prion protein expression on metal metabolism. Molecular and Cellular Neurosciences, 2009, 41, 135-147.	1.0	45
76	Î±-Synuclein increases Î²-amyloid secretion by promoting Î²-/Î³-secretase processing of APP. PLoS ONE, 2017, 12, e0171925.	1.1	45
77	A Prion Protein Fragment Primes Type 1 Astrocytes to Proliferation Signals from Microglia. Neurobiology of Disease, 1998, 4, 410-422.	2.1	44
78	Oligomeric alphaâ€synuclein and its role in neuronal death. IUBMB Life, 2010, 62, 334-339.	1.5	44
79	Prion protein expression modulates neuronal copper content. Journal of Neurochemistry, 2003, 87, 377-385.	2.1	43
80	Raman Optical Activity and Circular Dichroism Reveal Dramatic Differences in the Influence of Divalent Copper and Manganese Ions on Prion Protein Folding. Biochemistry, 2008, 47, 2510-2517.	1.2	43
81	A Model for the Mechanism of Astrogliosis in Prion Disease. Molecular and Cellular Neurosciences, 2000, 16, 221-232.	1.0	42
82	Analysis of doppel protein toxicity. Molecular and Cellular Neurosciences, 2003, 23, 144-155.	1.0	41
83	An Aggregation-Specific Enzyme-Linked Immunosorbent Assay: Detection of Conformational Differences between Recombinant PrP Protein Dimers and PrP Sc Aggregates. Journal of Virology, 2005, 79, 12355-12364.	1.5	41
84	Evaluation of Copper²⁺ Affinities for the Prion Protein. Biochemistry, 2009, 48, 8929-8931.	1.2	40
85	Prions and manganese: A maddening beast. Metallomics, 2011, 3, 229-238.	1.0	40
86	PrPSc-like prion protein peptide inhibits the function of cellular prion protein. Biochemical Journal, 2000, 352, 511.	1.7	39
87	Alpha-synuclein and its role in metal binding: Relevance to Parkinson's disease. Journal of Neuroscience Research, 2008, 86, 496-503.	1.3	39
88	Prion protein fragment interacts with PrP-deficient cells. Journal of Neuroscience Research, 1998, 52, 260-267.	1.3	37
89	Cellular uptake of the prion protein fragment PrP106-126 in vitro. Journal of Neurocytology, 1999, 28, 149-159.	1.6	36
90	Altered toxicity of the prion protein peptide PrP106â€“126 carrying the Ala117â†'Val mutation. Biochemical Journal, 2000, 346, 785-791.	1.7	36

#	Article	IF	Citations
91	NMR characterization of the pH 4 Î²-intermediate of the prion protein: the N-terminal half of the protein remains unstructured and retains a high degree of flexibility. Biochemical Journal, 2007, 401, 533-540.	1.7	36
92	Role of Microglia in Age-Related Changes to the Nervous System. Scientific World Journal, The, 2009, 9, 1061-1071.	0.8	36
93	Mapping the functional domain of the prion protein. FEBS Journal, 2003, 270, 3368-3376.	0.2	35
94	Prion protein reduces both oxidative and non-oxidative copper toxicity. Journal of Neurochemistry, 2006, 98, 677-689.	2.1	35
95	Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. NeuroReport, 2003, 14, 1743-1745.	0.6	34
96	Surround optical fiber immunoassay (SOFIA): An ultra-sensitive assay for prion protein detection. Journal of Virological Methods, 2009, 159, 15-22.	1.0	34
97	Copper-dependent co-internalization of the prion protein and glypican-1. Journal of Neurochemistry, 2006, 98, 1445-1457.	2.1	32
98	Alpha-synuclein: relating metals to structure, function and inhibition. Metallomics, 2016, 8, 385-397.	1.0	31
99	Prion protein-overexpressing cells show altered response to a neurotoxic prion protein peptide. Journal of Neuroscience Research, 1998, 54, 331-340.	1.3	30
100	Astrocytes Regulate N-Methyl-d-aspartate Receptor Subunit Composition Increasing Neuronal Sensitivity to Excitotoxicity. Journal of Biological Chemistry, 2001, 276, 22446-22452.	1.6	30
101	Toxicity of novel C-terminal prion protein fragments and peptides harbouring disease-related C-terminal mutations. FEBS Journal, 2001, 268, 6155-6164.	0.2	30
102	Re-partitioning of Cu and Zn isotopes by modified protein expression. Geochemical Transactions, 2008, 9, 11.	1.8	30
103	Metalloproteins and neuronal death. Metallomics, 2010, 2, 186-194.	1.0	30
104	Senescent Microglia: The Key to the Ageing Brain?. International Journal of Molecular Sciences, 2021, 22, 4402.	1.8	30
105	Mayhem of the multiple mechanisms: modelling neurodegeneration in prion disease. Journal of Neurochemistry, 2002, 82, 209-215.	2.1	29
106	Mouse galectin-1 inhibits the toxicity of glutamate by modifying NR1 NMDA receptor expression. European Journal of Neuroscience, 2006, 24, 3017-3025.	1.2	29
107	High affinity copper binding by stefin B (cystatin B) and its role in the inhibition of amyloid fibrillation. FEBS Journal, 2006, 273, 4250-4263.	2.2	29
108	Real-time kinetics of discontinuous and highly conformational metal-ion binding sites of prion protein. Journal of Biological Inorganic Chemistry, 2007, 12, 711-720.	1.1	29

#	Article	IF	Citations
109	Dynamics of a truncated prion protein, PrP(113â€“231), from ¹⁵N NMR relaxation: Order parameters calculated and slow conformational fluctuations localized to a distinct region. Protein Science, 2009, 18, 410-423.	3.1	28
110	Inhibition of tumour necrosis factor-Î± (TNFÎ±)-induced NF-ÎºB p52 converts the metabolic effects of microglial-derived TNFÎ± on mouse cerebellar neurones to neurotoxicity. Journal of Neurochemistry, 2001, 76, 1431-1438.	2.1	26
111	Altered Processing of Î²-Amyloid in SH-SY5Y Cells Induced by Model Senescent Microglia. ACS Chemical Neuroscience, 2018, 9, 3137-3152.	1.7	25
112	A novel method of generating neuronal cell lines from gene-knockout mice to study prion protein membrane orientation. European Journal of Neuroscience, 2003, 18, 571-579.	1.2	24
113	Hydrogen peroxide cleavage of the prion protein generates a fragment able to initiate polymerisation of full length prion protein. International Journal of Biochemistry and Cell Biology, 2006, 38, 1429-1440.	1.2	24
114	Cellular effects of a neurotoxic prion protein peptide are related to its ?-sheet content. Neuroscience Research Communications, 1998, 23, 119-128.	0.2	23
115	Dual polarisation interferometry analysis of copper binding to the prion protein: Evidence for two folding states. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 920-927.	1.1	22
116	Metal attenuating therapies in neurodegenerative disease. Expert Review of Neurotherapeutics, 2011, 11, 1717-1745.	1.4	22
117	Purification and preparation of prion protein: Synaptic superoxide dismutase. Methods in Enzymology, 2002, 349, 258-267.	0.4	21
118	Contribution of Individual Histidines to Prion Protein Copper Binding. Biochemistry, 2011, 50, 10781-10791.	1.2	21
119	Steady-State Kinetics of Î±-Synuclein Ferrireductase Activity Identifies the Catalytically Competent Species. Biochemistry, 2017, 56, 2497-2505.	1.2	21
120	Functional and structural differences between the prion protein from two alleles prnpa and prnpb of mouse. FEBS Journal, 2000, 267, 2452-2459.	0.2	19
121	Resistance of cell lines to prion toxicity aided by phospho-ERK expression. Journal of Neurochemistry, 2008, 105, 842-852.	2.1	19
122	The Catalytic Redox Activity of Prion Proteinâ€“Cu^{II} is Controlled by Metal Exchange with the Zn^{II}â€“Thiolate Clusters of Zn₇Metallothioneinâ€ƀ. ChemBioChem, 2012, 13, 1261-1265.	1.3	18
123	Nrf-2 regulation of prion protein expression is independent of oxidative stress. Molecular and Cellular Neurosciences, 2014, 63, 31-37.	1.0	18
124	Iron, Aging, and Neurodegeneration. Metals, 2015, 5, 2070-2092.	1.0	18
125	Alpha-synuclein ferrireductase activity is detectible in vivo, is altered in Parkinson's disease and increases the neurotoxicity of DOPAL. Molecular and Cellular Neurosciences, 2017, 85, 1-11.	1.0	18
126	Regulation of Prion Protein Expression by Noncoding Regions of the Prnp Gene. Journal of Molecular Biology, 2007, 368, 915-927.	2.0	17

#	Article	IF	Citations
127	Counter-regulation of alpha- and beta-synuclein expression at the transcriptional level. Molecular and Cellular Neurosciences, 2013, 57, 33-41.	1.0	17
128	Model Senescent Microglia Induce Disease Related Changes in Î±-Synuclein Expression and Activity. Biomolecules, 2018, 8, 67.	1.8	17
129	Transcriptional Regulation of the Beta-Synuclein 5â€²-Promoter Metal Response Element by Metal Transcription Factor-1. PLoS ONE, 2011, 6, e17354.	1.1	17
130	Astrocytic regulation of NMDA receptor subunit composition modulates the toxicity of prion peptide PrP106â€“126. Molecular and Cellular Neurosciences, 2004, 25, 181-191.	1.0	16
131	Mechanistic Insights into the Cure of Prion Disease by Novel Antiprion Compounds. Journal of Virology, 2007, 81, 10729-10741.	1.5	16
132	Metals in neurodegenerative disease. Metallomics, 2011, 3, 226.	1.0	16
133	BSE and vCJD cause disturbance to uric acid levels. Experimental Neurology, 2004, 190, 233-244.	2.0	14
134	Ancient conserved domain proteinâ€1 binds copper and modifies its retention in cells. Journal of Neurochemistry, 2007, 103, 312-321.	2.1	13
135	Metallic prions. Biochemical Society Symposia, 2004, 71, 193-202.	2.7	13
136	Anterograde axonal transport of the exogenous cellular isoform of prion protein in the chick visual system. Molecular and Cellular Neurosciences, 2006, 31, 97-108.	1.0	12
137	Mechanisms of Prion Protein Aggregation. Protein and Peptide Letters, 2009, 16, 14-26.	0.4	12
138	Prion protein expression alters APP cleavage without interaction with BACE-1. Neurochemistry International, 2012, 61, 672-680.	1.9	12
139	Prion protein polymerisation triggered by manganeseâ€generated prion protein seeds. Journal of Neurochemistry, 2012, 120, 177-189.	2.1	12
140	Comment on: Neurotoxicity of prion peptide 106-126 not confirmed. FEBS Letters, 1999, 460, 559-560.	1.3	11
141	Activation and repression of prion protein expression by key regions of intron 1. Cellular and Molecular Life Sciences, 2009, 66, 3809-3820.	2.4	11
142	Altered toxicity of the prion protein peptide PrP106â€'126 carrying the Ala117â†'Val mutation. Biochemical Journal, 2000, 346, 785.	1.7	9
143	Levels of Î±â€•and Î²â€‹synuclein regulate cellular susceptibility to toxicity from Î±â€‹synuclein oligomers. FASEB Journal, 2018, 32, 995-1006.	0.2	9
144	Molecular Advances in Understanding Inherited Prion Diseases. Molecular Neurobiology, 2002, 25, 287-302.	1.9	8

#	Article	IF	Citations
145	Evaluation of Î²â€Alanineâ€•and GABAâ€Substituted Peptides as Inhibitors of Diseaseâ€Linked Protein Aggregation. ChemBioChem, 2009, 10, 1982-1987.	1.3	8
146	Anterograde axonal transport of chicken cellular prion protein (PrPc) in vivo requires its N-terminal part. Journal of Neuroscience Research, 2007, 85, 2567-2579.	1.3	7
147	Amyloidogenic metal-binding proteins: new investigative pathways. Biochemical Society Transactions, 2008, 36, 1299-1303.	1.6	7
148	Prion infection in cells is abolished by a mutated manganese transporter but shows no relation to zinc. Molecular and Cellular Neurosciences, 2015, 68, 186-193.	1.0	7
149	Catecholamine-Directed Epithelial Cell Interactions with Bacteria in the Intestinal Mucosa. Advances in Experimental Medicine and Biology, 2016, 874, 79-99.	0.8	6
150	Synthesis and testing of peptides for anti-prion activity. European Journal of Medicinal Chemistry, 2008, 43, 2418-2427.	2.6	4
151	Introduction: Copper and amyloid fibril formation. FEBS Journal, 2007, 274, 3755-3755.	2.2	3
152	Metals and Prions: Twenty Years of Mining the Awe. , 2017, , 95-115.		3
153	Investigation of PrPC Metabolism and Function in Live Cells. Methods in Molecular Biology, 2008, 459, 21-34.	0.4	3
154	Prion Protein Peptide: Agents of Death for Neurons. , 2001, 59, 51-70.		2
155	Modelling neurodegeneration in prion disease â€“ applications for drug development. Expert Opinion on Drug Discovery, 2007, 2, 777-788.	2.5	1
156	Copper and Prion Disease. , 2003, , 279-305.		1
157	Effect of copper on recombinant mouse prion protein. Biochemical Society Transactions, 2000, 28, A36-A36.	1.6	0
158	Conformational exposure: a new handle on prions. Lancet, The, 2003, 362, 929-930.	6.3	0
159	A Stone Guest on the Brain: Death as a Prion. , 2005, , 241-271.		0
160	The use of peptides that pick up prions: protection or poison?. Expert Opinion on Therapeutic Patents, 2005, 15, 1287-1290.	2.4	0
161	Metallic Prions: Mining the Core of Transmissible Spongiform Encephalopathies. , 2006, , 89-114.		0
162	Gene regulation as a potential avenue for the treatment of neurodegenerative disorders. Expert Opinion on Drug Discovery, 2009, 4, 515-524.	2.5	0